These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 39017899)

  • 1. Comparing the risk of severe oral mucositis associated with methotrexate as graft-versus host-disease prophylaxis to other immunosuppressive prophylactic agents in hematopoietic cell transplantation: a systematic review and meta-analysis.
    Al-Jamaei AAH; Epstein JB; de Visscher JGAM; Spielberger RT; Nakamura R; Raber-Durlacher JE
    Support Care Cancer; 2024 Jul; 32(8):519. PubMed ID: 39017899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
    Kharfan-Dabaja M; Mhaskar R; Reljic T; Pidala J; Perkins JB; Djulbegovic B; Kumar A
    Cochrane Database Syst Rev; 2014 Jul; 2014(7):CD010280. PubMed ID: 25061777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD.
    Sugita J; Matsushita T; Kashiwazaki H; Kosugi M; Takahashi S; Wakasa K; Shiratori S; Ibata M; Shono Y; Shigematsu A; Obara M; Fujimoto K; Endo T; Nishio M; Kondo T; Hashino S; Tanaka J; Asaka M; Imamura M
    Bone Marrow Transplant; 2012 Feb; 47(2):258-64. PubMed ID: 21423118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus/methotrexate vs tacrolimus/reduced-dose methotrexate/mycophenolate for graft-versus-host disease prevention.
    Hamilton BK; Rybicki LA; Li H; Lucas T; Corrigan D; Kalaycio M; Sobecks R; Hanna R; Rotz SJ; Dean RM; Gerds AT; Jagadeesh D; Brunstein C; Sauter CS; Copelan EA; Majhail NS
    Blood Adv; 2023 Aug; 7(16):4505-4513. PubMed ID: 37352262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
    Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
    Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of folinic acid in methotrexate-based prophylaxis of graft-versus-host disease following hematopoietic stem cell transplantation.
    AlJohani NI
    Hematology; 2021 Dec; 26(1):620-627. PubMed ID: 34411497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil vs. methotrexate for the prevention of graft-versus-host-disease--systematic review and meta-analysis.
    Ram R; Yeshurun M; Vidal L; Shpilberg O; Gafter-Gvili A
    Leuk Res; 2014 Mar; 38(3):352-60. PubMed ID: 24418750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
    Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral mucositis after tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host disease prophylaxis.
    Garming Legert K; Ringdén O; Remberger M; Törlén J; Mattsson J; Dahllöf G
    Oral Dis; 2021 Jul; 27(5):1217-1225. PubMed ID: 33012083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT.
    Hudspeth MP; Heath TS; Chiuzan C; Garrett-Mayer E; Nista E; Burton L; Ragucci D
    Bone Marrow Transplant; 2013 Jan; 48(1):46-9. PubMed ID: 22609886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of calcineurin inhibitors in combination with conventional methotrexate, reduced methotrexate, or mycophenolate mofetil for prophylaxis of graft-versus-host disease after umbilical cord blood transplantation.
    Yoshida S; Ohno Y; Nagafuji K; Yoshimoto G; Sugio T; Kamimura T; Ohta T; Takase K; Henzan H; Muta T; Iwasaki H; Ogawa R; Eto T; Akashi K; Miyamoto T
    Ann Hematol; 2019 Nov; 98(11):2579-2591. PubMed ID: 31628517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review.
    Chaudhry HM; Bruce AJ; Wolf RC; Litzow MR; Hogan WJ; Patnaik MS; Kremers WK; Phillips GL; Hashmi SK
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):605-616. PubMed ID: 26409924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
    Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
    Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
    Piñana JL; Valcárcel D; Fernández-Avilés F; Martino R; Rovira M; Barba P; Martínez C; Brunet S; Sureda A; Carreras E; Sierra J
    Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay.
    Freyer CW; Gier S; Moyer ME; Berryman N; Carulli A; Ganetsky A; Timlin C; Babushok DV; Frey NV; Gill SI; Hexner EO; Loren AW; Mangan JK; Martin ME; McCurdy S; Perl AE; Smith J; Luger SM; Stadtmauer EA; Porter DL
    Transplant Cell Ther; 2021 May; 27(5):431.e1-431.e8. PubMed ID: 33965188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folic acid supplementation during methotrexate immunosuppression is not associated with early toxicity, risk of acute graft-versus-host disease or relapse following hematopoietic transplantation.
    Robien K; Schubert MM; Yasui Y; Martin P; Storb R; Potter JD; Ulrich CM
    Bone Marrow Transplant; 2006 Apr; 37(7):687-92. PubMed ID: 16501595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
    Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
    Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplantation Cyclophosphamide-based Graft-versus-host-disease Prophylaxis Compared to Methotrexate-cyclosporine a in Matched-related Allogeneic Hematopoietic Stem Cell Transplantation.
    Shouman MT; Mansour OM; El Gammal MM; Abdel-Fattah RM; Samra MA; Elhaddad AM; Maher MA; Mahmoud HK
    Hematol Oncol Stem Cell Ther; 2023 May; 16(4):379-387. PubMed ID: 37363983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective effect of cryotherapy against oral mucositis among allogeneic hematopoietic stem cell transplant recipients using melphalan-based conditioning.
    Oku S; Futatsuki T; Imamura Y; Hikita H; Inada A; Mizutani S; Mori Y; Kashiwazaki H
    Support Care Cancer; 2023 Aug; 31(9):521. PubMed ID: 37581845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.